Medical therapy after successful percutaneous coronary revascularization

David Hasdai, Amir Lerman, Diane E. Grill, Charanjit Rihal, David Holmes

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Percutaneous coronary revascularization frequently relieves angina in patients with ischemic heart disease and may obviate the need for antianginal medications. Objective: To examine the use of antianginal medications after successful percutaneous coronary revascularization. Design: Retrospective cohort study of the Mayo Clinic PTCA [percutaneous transluminal coronary angioplasty] Registry. Setting: Tertiary care center. Patients: 3831 patients who underwent successful percutaneous coronary revascularization from September 1979 through August 1997 and had not had myocardial infarction within the year before the intervention. Measurements: Use of antianginal medications (β-adrenergic blockers, nitrates, and calcium-channel blockers) before the intervention, at hospital discharge, and 6 months after the intervention. Results: 99% of patients reported improvement in their symptoms at hospital discharge. At 6 months, 87% of patients were free of myocardial infarction, coronary bypass surgery, or additional percutaneous intervention. Compared with 66% of patients before the index intervention, only 12% of patients had severe angina at 6 months and 69% were completely free of angina. Nonetheless, at 6 months, 39% of patients were receiving β- adrenergic blockers (preprocedure proportion, 43%; P ≤ 0.001), 36% were receiving nitrates (preprocedure proportion, 41%; P≤0.001), and 57% were receiving calcium-channel blockers (preprocedure proportion, 50%; P≤0.001). These trends persisted for patients without hypertension and those who had complete revascularization. Conclusions: Successful percutaneous coronary revascularization did not substantially supplant the use of antianginal medications, which were commonly used despite the marked improvement in anginal status. This may reflect reluctance to alter therapy once symptoms of angina subside. Guidelines on continued medical therapy after percutaneous coronary revascularization are needed.

Original languageEnglish (US)
Pages (from-to)108-115
Number of pages8
JournalAnnals of Internal Medicine
Volume130
Issue number2
StatePublished - Jan 19 1999

Fingerprint

Percutaneous Coronary Intervention
Adrenergic Antagonists
Therapeutics
Calcium Channel Blockers
Nitrates
Myocardial Infarction
Coronary Balloon Angioplasty
Tertiary Care Centers
Myocardial Ischemia
Registries
Cohort Studies
Retrospective Studies
Guidelines
Hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Medical therapy after successful percutaneous coronary revascularization. / Hasdai, David; Lerman, Amir; Grill, Diane E.; Rihal, Charanjit; Holmes, David.

In: Annals of Internal Medicine, Vol. 130, No. 2, 19.01.1999, p. 108-115.

Research output: Contribution to journalArticle

Hasdai, David ; Lerman, Amir ; Grill, Diane E. ; Rihal, Charanjit ; Holmes, David. / Medical therapy after successful percutaneous coronary revascularization. In: Annals of Internal Medicine. 1999 ; Vol. 130, No. 2. pp. 108-115.
@article{0e95995b2538439b9ee9b8c59ab063fa,
title = "Medical therapy after successful percutaneous coronary revascularization",
abstract = "Background: Percutaneous coronary revascularization frequently relieves angina in patients with ischemic heart disease and may obviate the need for antianginal medications. Objective: To examine the use of antianginal medications after successful percutaneous coronary revascularization. Design: Retrospective cohort study of the Mayo Clinic PTCA [percutaneous transluminal coronary angioplasty] Registry. Setting: Tertiary care center. Patients: 3831 patients who underwent successful percutaneous coronary revascularization from September 1979 through August 1997 and had not had myocardial infarction within the year before the intervention. Measurements: Use of antianginal medications (β-adrenergic blockers, nitrates, and calcium-channel blockers) before the intervention, at hospital discharge, and 6 months after the intervention. Results: 99{\%} of patients reported improvement in their symptoms at hospital discharge. At 6 months, 87{\%} of patients were free of myocardial infarction, coronary bypass surgery, or additional percutaneous intervention. Compared with 66{\%} of patients before the index intervention, only 12{\%} of patients had severe angina at 6 months and 69{\%} were completely free of angina. Nonetheless, at 6 months, 39{\%} of patients were receiving β- adrenergic blockers (preprocedure proportion, 43{\%}; P ≤ 0.001), 36{\%} were receiving nitrates (preprocedure proportion, 41{\%}; P≤0.001), and 57{\%} were receiving calcium-channel blockers (preprocedure proportion, 50{\%}; P≤0.001). These trends persisted for patients without hypertension and those who had complete revascularization. Conclusions: Successful percutaneous coronary revascularization did not substantially supplant the use of antianginal medications, which were commonly used despite the marked improvement in anginal status. This may reflect reluctance to alter therapy once symptoms of angina subside. Guidelines on continued medical therapy after percutaneous coronary revascularization are needed.",
author = "David Hasdai and Amir Lerman and Grill, {Diane E.} and Charanjit Rihal and David Holmes",
year = "1999",
month = "1",
day = "19",
language = "English (US)",
volume = "130",
pages = "108--115",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "2",

}

TY - JOUR

T1 - Medical therapy after successful percutaneous coronary revascularization

AU - Hasdai, David

AU - Lerman, Amir

AU - Grill, Diane E.

AU - Rihal, Charanjit

AU - Holmes, David

PY - 1999/1/19

Y1 - 1999/1/19

N2 - Background: Percutaneous coronary revascularization frequently relieves angina in patients with ischemic heart disease and may obviate the need for antianginal medications. Objective: To examine the use of antianginal medications after successful percutaneous coronary revascularization. Design: Retrospective cohort study of the Mayo Clinic PTCA [percutaneous transluminal coronary angioplasty] Registry. Setting: Tertiary care center. Patients: 3831 patients who underwent successful percutaneous coronary revascularization from September 1979 through August 1997 and had not had myocardial infarction within the year before the intervention. Measurements: Use of antianginal medications (β-adrenergic blockers, nitrates, and calcium-channel blockers) before the intervention, at hospital discharge, and 6 months after the intervention. Results: 99% of patients reported improvement in their symptoms at hospital discharge. At 6 months, 87% of patients were free of myocardial infarction, coronary bypass surgery, or additional percutaneous intervention. Compared with 66% of patients before the index intervention, only 12% of patients had severe angina at 6 months and 69% were completely free of angina. Nonetheless, at 6 months, 39% of patients were receiving β- adrenergic blockers (preprocedure proportion, 43%; P ≤ 0.001), 36% were receiving nitrates (preprocedure proportion, 41%; P≤0.001), and 57% were receiving calcium-channel blockers (preprocedure proportion, 50%; P≤0.001). These trends persisted for patients without hypertension and those who had complete revascularization. Conclusions: Successful percutaneous coronary revascularization did not substantially supplant the use of antianginal medications, which were commonly used despite the marked improvement in anginal status. This may reflect reluctance to alter therapy once symptoms of angina subside. Guidelines on continued medical therapy after percutaneous coronary revascularization are needed.

AB - Background: Percutaneous coronary revascularization frequently relieves angina in patients with ischemic heart disease and may obviate the need for antianginal medications. Objective: To examine the use of antianginal medications after successful percutaneous coronary revascularization. Design: Retrospective cohort study of the Mayo Clinic PTCA [percutaneous transluminal coronary angioplasty] Registry. Setting: Tertiary care center. Patients: 3831 patients who underwent successful percutaneous coronary revascularization from September 1979 through August 1997 and had not had myocardial infarction within the year before the intervention. Measurements: Use of antianginal medications (β-adrenergic blockers, nitrates, and calcium-channel blockers) before the intervention, at hospital discharge, and 6 months after the intervention. Results: 99% of patients reported improvement in their symptoms at hospital discharge. At 6 months, 87% of patients were free of myocardial infarction, coronary bypass surgery, or additional percutaneous intervention. Compared with 66% of patients before the index intervention, only 12% of patients had severe angina at 6 months and 69% were completely free of angina. Nonetheless, at 6 months, 39% of patients were receiving β- adrenergic blockers (preprocedure proportion, 43%; P ≤ 0.001), 36% were receiving nitrates (preprocedure proportion, 41%; P≤0.001), and 57% were receiving calcium-channel blockers (preprocedure proportion, 50%; P≤0.001). These trends persisted for patients without hypertension and those who had complete revascularization. Conclusions: Successful percutaneous coronary revascularization did not substantially supplant the use of antianginal medications, which were commonly used despite the marked improvement in anginal status. This may reflect reluctance to alter therapy once symptoms of angina subside. Guidelines on continued medical therapy after percutaneous coronary revascularization are needed.

UR - http://www.scopus.com/inward/record.url?scp=0033582164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033582164&partnerID=8YFLogxK

M3 - Article

C2 - 10068356

AN - SCOPUS:0033582164

VL - 130

SP - 108

EP - 115

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 2

ER -